Skip to main content

Table 5 Incidence of parkinsonian events (SAS)

From: Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial

AE

PLA-DON10

DON5-DON10

DON10-DON10

DON-DON10 a

( n =37)

( n =47)

( n =49)

( n =96)

Subjects with any parkinsonian events, n (%)

5 (13.5)

3 (6.4)

9 (18.4)

12 (12.5)

Camptocormia

0

0

1 (2.0)

1 (1.0)

Akinesia

1 (2.7)

0

0

0

Parkinsonism

3 (8.1)

3 (6.4)

9 (18.4)

12 (12.5)

Tremor

1 (2.7)

0

0

0

  1. SAS, safety analysis set; AE, adverse event.
  2. aDON5-DON10 and DON10-DON10 groups.